JP2018529717A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529717A5
JP2018529717A5 JP2018516214A JP2018516214A JP2018529717A5 JP 2018529717 A5 JP2018529717 A5 JP 2018529717A5 JP 2018516214 A JP2018516214 A JP 2018516214A JP 2018516214 A JP2018516214 A JP 2018516214A JP 2018529717 A5 JP2018529717 A5 JP 2018529717A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
antigen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516214A
Other languages
English (en)
Japanese (ja)
Other versions
JP6764930B2 (ja
JP2018529717A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2016/004375 external-priority patent/WO2017056494A1/en
Publication of JP2018529717A publication Critical patent/JP2018529717A/ja
Publication of JP2018529717A5 publication Critical patent/JP2018529717A5/ja
Application granted granted Critical
Publication of JP6764930B2 publication Critical patent/JP6764930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516214A 2015-09-29 2016-09-28 アデニンコンジュゲート化合物およびそのワクチンアジュバントとしての使用 Active JP6764930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234481P 2015-09-29 2015-09-29
US62/234,481 2015-09-29
PCT/JP2016/004375 WO2017056494A1 (en) 2015-09-29 2016-09-28 Adenine conjugate compounds and their use as vaccine adjuvants

Publications (3)

Publication Number Publication Date
JP2018529717A JP2018529717A (ja) 2018-10-11
JP2018529717A5 true JP2018529717A5 (cg-RX-API-DMAC7.html) 2019-11-07
JP6764930B2 JP6764930B2 (ja) 2020-10-07

Family

ID=57138095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516214A Active JP6764930B2 (ja) 2015-09-29 2016-09-28 アデニンコンジュゲート化合物およびそのワクチンアジュバントとしての使用

Country Status (8)

Country Link
US (1) US10597397B2 (cg-RX-API-DMAC7.html)
EP (1) EP3355933B1 (cg-RX-API-DMAC7.html)
JP (1) JP6764930B2 (cg-RX-API-DMAC7.html)
CN (1) CN108348618B (cg-RX-API-DMAC7.html)
CA (1) CA2998995A1 (cg-RX-API-DMAC7.html)
DK (1) DK3355933T3 (cg-RX-API-DMAC7.html)
ES (1) ES2805724T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017056494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998995A1 (en) * 2015-09-29 2017-04-06 Astrazeneca Aktiebolag Adenine conjugate compounds and their use as vaccine adjuvants
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
AU2019311965B2 (en) 2018-07-23 2026-02-19 Japan Institute For Health Security Composition containing influenza vaccine
SG11202109566XA (en) * 2019-03-04 2021-10-28 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for preparing influenza ha split vaccine
CA3136066A1 (en) * 2019-04-05 2020-10-08 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant and composition containing same
WO2024020684A1 (en) * 2022-07-26 2024-02-01 Zymeworks Bc Inc. Immunomodulator purine-derived compounds, conjugates thereof, and methods of use thereof
JP2026514385A (ja) * 2023-03-27 2026-05-11 ザ クリーブランド クリニック ファウンデーション がんのためのpala局所療法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
EP1617872A4 (en) 2003-04-10 2011-09-07 3M Innovative Properties Co METHOD AND COMPOSITIONS FOR IMPROVING THE IMMUNE RESPONSE
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
EP2510946B1 (en) * 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
PT2341933T (pt) 2008-10-24 2018-02-13 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
US9044481B2 (en) 2009-08-07 2015-06-02 Glaxosmithkline Biologicals S.A. Lipidated oxoadenine derivatives
EP2563366A4 (en) * 2010-04-30 2013-11-20 Univ California USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
WO2012011606A1 (en) 2010-07-20 2012-01-26 Dainippon Sumitomo Pharma Co., Ltd. Process for preparing adenine compounds and intermediates thereof
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
FR2968662B1 (fr) * 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
CA2998995A1 (en) * 2015-09-29 2017-04-06 Astrazeneca Aktiebolag Adenine conjugate compounds and their use as vaccine adjuvants

Similar Documents

Publication Publication Date Title
US7893096B2 (en) Use of small molecule compounds for immunopotentiation
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
JP2013510124A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2011503045A (ja) Crth2拮抗化合物の使用
JP6030739B2 (ja) Iap阻害剤による免疫調節
JP2013510120A5 (cg-RX-API-DMAC7.html)
EP3129379A1 (en) Mertk-specific pyrrolopyrimidine compounds
CN116712552A (zh) 用于治疗疱疹病毒诱导的病况的方法和组合物
JP2014513110A5 (cg-RX-API-DMAC7.html)
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
JP2018531987A5 (cg-RX-API-DMAC7.html)
JP2020531593A5 (cg-RX-API-DMAC7.html)
JP2009507896A5 (cg-RX-API-DMAC7.html)
UY32695A (es) FORMA DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL DE UN INHIBIDOR DE LA FAMILIA Bcl-2
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
JP2023510719A (ja) コロナウイルス感染症の治療方法
CA2568608A1 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
JP2010523477A5 (cg-RX-API-DMAC7.html)
JP2014505107A5 (cg-RX-API-DMAC7.html)
JP2016531895A5 (cg-RX-API-DMAC7.html)
JP2015529194A5 (cg-RX-API-DMAC7.html)
JP2009541387A5 (cg-RX-API-DMAC7.html)
JP2009515814A5 (cg-RX-API-DMAC7.html)